Houston, United States
March Biosciences is a disruptive force in the health care industry, aiming to revolutionize patient care for the most challenging hematological malignancies. With the slogan "Transforming patient care in the most challenging leukemias and lymphomas," March Biosciences, Inc. has positioned itself as a clinical-stage cell therapy company on a mission to make a difference. Founded in 2021 and headquartered in the United States, the company has made significant progress, with its lead asset reaching the end of Phase I trials for T-cell malignancies, diseases with a poor prognosis currently unaddressed by CAR-T and targeted therapy technologies.
Notably, March Biosciences recently secured a $13.40M grant investment on 15 November 2023 from the Cancer Prevention and Research Institute of Texas, signaling confidence in the company's potential for transforming the landscape of cancer treatment. The company's pipeline is strategically designed to build upon these early successes and extend its impact to other high-challenge cancers, underscoring its dedication to providing solutions to unmet medical needs. With its innovative approach and recent investment backing, March Biosciences is poised to be a game-changer in the fight against hematological malignancies.
